Silver Book Fact

Assuming that Medicare Part D covers about 37% of beneficiaries’ drug costs, it is estimated that providing post-myocardial infarction Medicare beneficiaries with full coverage for combination pharmcotherapy will save more than $5,600 per patient over a 3-year period.

Choudhry N, Avorn J, Antman EM, Schneeweiss S, Shrank WH. Should Patients Receive Secondary Prevention Medications For Free After A Myocardial Infarction? An economic analysis. Health Affairs. 2007; 26(1): 186-194. https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.26.1.186?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed

Reference

Title
Should Patients Receive Secondary Prevention Medications For Free After A Myocardial Infarction? An economic analysis
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Choudhry N, Avorn J, Antman EM, Schneeweiss S, Shrank WH
Volume & Issue
Volume 26, Issue 1
Pages
186-194
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Initiating and continuing beta-blocker use in most first-time heart attack survivors for 20 years would result in 72,000 fewer coronary heart disease deaths, 62,000 fewer heart attacks, and 447,000 gained…  
  • Several prevention/early detection interventions for cardiovascular disease have cost-effectiveness ratios of $50,000-$70,000 per life saved.  
  • Effectiveness of pacemaker/defibrillators to control AFib
    Widespread use of pacemaker/defibrillators to control atrial fibrillation could result in a 50% decrease in stroke.  
  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • The development of antioxidants that reduce oxidative damage is underway. One antioxidant that has been found, uric acid, has an even greater protective effect when combined with tPA.